Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Anticoagulant: binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin; also inactivates factors IX, XI, XII, and plasmin.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Atrial fibrillation with embolization,Treatment of acute coronary syndromes,As an anticoagulant for extracorporeal circuits and dialysis procedures
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Continuous IV infusion: 12-18 units/kg/hour, adjusted based on a PTT. Initial bolus of 60-80 units/kg may be given. Typical infusion rate for prophylaxis: 5,000 units subcutaneously every 8-12 hours.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal half-life: 1.5-2.5 hours (mean 1.7 h) for IV heparin; dose-dependent, increasing with higher doses (saturable clearance). In patients with renal impairment, half-life prolonged (up to 2-3 times).
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Primarily cleared by the reticuloendothelial system; partially metabolized by desulfation and depolymerization; renal excretion of metabolites.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: 50-60% as unchanged drug via urine; reticuloendothelial system: significant hepatic and splenic uptake with depolymerization; biliary: minor. Total clearance is dose-dependent due to saturable cellular binding.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Heparin binds to multiple plasma proteins: antithrombin III (ATIII) primarily (functional binding), but also to lipoproteins, histidine-rich glycoprotein, and platelet factor 4. Total protein binding: >90% (nonspecific binding).
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.05-0.07 L/kg (confined to plasma volume; ~5 L in 70 kg adult). Does not distribute into extravascular spaces. Increased Vd in pregnancy and obesity.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Subcutaneous: 20-30% (due to poor absorption, tissue binding, and first-pass degradation). IV: 100%. Not absorbed orally.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Not required; heparin is not renally cleared. However, monitor a PTT closely in patients with severe renal impairment (e GFR < 30 m L/min) due to increased bleeding risk.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Not recommended in severe hepatic impairment (Child-Pugh C) due to increased bleeding risk. In moderate impairment (Child-Pugh B), use with caution and monitor a PTT closely.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Loading dose: 75-100 units/kg IV over 10 minutes. Maintenance: Infants: 28 units/kg/hour; Children: 18-20 units/kg/hour; Adolescents: 18 units/kg/hour. Adjust to target a PTT.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Lower initial infusion rate (e.g., 10-12 units/kg/hour) due to increased sensitivity; monitor a PTT closely and reduce dose accordingly. Avoid subcutaneous if frail due to hematoma risk.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Spinal/epidural hematomas have occurred with neuraxial anesthesia or spinal puncture; monitor for signs of neurological impairment.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of hemorrhage: monitor coagulation tests (a PTT, anti-Xa) and platelet counts,Heparin-induced thrombocytopenia (HIT): discontinue if HIT suspected,Hypersensitivity reactions: can cause anaphylaxis,Hyperkalemia: may suppress aldosterone, monitor potassium in renal impairment
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
History of heparin-induced thrombocytopenia (HIT),Active bleeding or bleeding disorders (e.g., hemophilia, thrombocytopenia),Severe uncontrolled hypertension,Recent major surgery or trauma with high bleeding risk,Hypersensitivity to heparin or pork products
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No significant food interactions. Maintain adequate hydration and a balanced diet. Avoid excessive alcohol consumption as it may increase bleeding risk.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Heparin does not cross the placenta and is not teratogenic; no known fetal risk in any trimester.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Heparin is not excreted into breast milk due to its high molecular weight; compatible with breastfeeding. M/P ratio: not applicable.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy requires close monitoring; dose adjustments may be needed due to increased plasma volume and clearance; anti-Xa monitoring recommended to achieve therapeutic levels.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Administer via continuous IV infusion using an infusion pump; do not give IM. Monitor a PTT 6 hours after initiation and adjust dose per nomogram. For prophylaxis, subcutaneous injection is preferred. Use with caution in patients with thrombocytopenia or history of HIT. Protamine sulfate is the reversal agent.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Report any signs of bleeding: unusual bruising, dark stools, blood in urine, bleeding gums.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed.,Inform all healthcare providers that you are on heparin.,Do not stop or change the dose without consulting your doctor.,If you miss a dose, contact your healthcare provider immediately.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Anticoagulant: binds to antithrombin III, enhancing its inhibition of factor Xa and thrombin; also inactivates factors IX, XI, XII, and plasmin.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Continuous IV infusion: 12-18 units/kg/hour, adjusted based on a PTT. Initial bolus of 60-80 units/kg may be given. Typical infusion rate for prophylaxis: 5,000 units subcutaneously every 8-12 hours.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Heparin does not cross the placenta and is not teratogenic; no known fetal risk in any trimester.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.